No effect of maraviroc on early immune cell reconstitution. (A) ALC from peripheral blood of control and maraviroc-treated patients at the indicated time points. (B) CD4⁺ T-cell count from control and maraviroc-treated patients at day 30 (P = .79, Mann-Whitney U test). (C) CD8⁺ T-cell count at day 30 (P = .93). (D) NK-cell count at day 30 (P = .28). (E) Absolute RTE count as represented by CD31⁺CD45RO⁻CCR7⁺CD4⁺ T cells at day 30 (P = .32). (F) Numbers of CD25⁺Foxp3⁺CD4⁺ T_regs at day 30 (P = .15).